Xin Lang Cai Jing·2026-02-10 03:34Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index (HSSCID) has surged by 4.32%, while the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) has increased by 3.50%, marking a three-day consecutive rise [1] - Innovent Biologics has entered into a global strategic collaboration with Eli Lilly to advance the development of new drugs in oncology and immunology, with a deal size exceeding expectations [1] - Under the agreement, Innovent will lead the research and development of related projects from drug discovery to clinical proof of concept in China, while Eli Lilly will obtain exclusive development and commercialization rights outside Greater China [1] Group 2 - According to Zhongyou Securities, although the innovative drug sector has experienced short-term fluctuations due to funding issues, the global participation trend has been fully reflected in 2025 [2] - Domestic new drugs are transitioning from early research to a phase of efficiency, indicating that the innovative drug sector is expected to enter a harvest period in the medium term [2] - The E Fund Hong Kong Stock Connect Innovative Drug ETF closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [2]